Cellular delivery of a double-stranded oligonucleotide NFκB decoy by hybridization to complementary PNA linked to a cell-penetrating peptide

Gene Therapy

Volumn 11, Issue 16, 2004, Pages 1264-1272

  Fisher, L ^a   Soomets, U ^a,b   Cortes Toro V ^a   Chilton, L ^a   Jiang, Y ^a   Langel, U ^a   Iverfeldt, K ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b UNIVERSITY OF TARTU   (Estonia)

Author keywords

Interleukin 1 ; Interleukin 6; NF B; Nuclear factor decoy; PNA; Transport peptide

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CARRIER PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; OLIGONUCLEOTIDE; PEPTIDE NUCLEIC ACID; TRANSPORTAN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL BASED GENE THERAPY; CELL MEMBRANE; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONSENSUS SEQUENCE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG UPTAKE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENE LOCATION; INCUBATION TIME; INSULINOMA; MOLECULAR HYBRIDIZATION; MOLECULAR STABILITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INDUCTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TERMINAL SEQUENCE; TUMOR CELL;

ANIMALS; BASE SEQUENCE; DRUG CARRIERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GALANIN; GENE EXPRESSION; INTERLEUKIN-1; INTERLEUKIN-6; MODELS, GENETIC; NUCLEIC ACID HYBRIDIZATION; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES; PEPTIDE NUCLEIC ACIDS; RATS; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; WASP VENOMS;

EID: 4444361522     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302291     Document Type: Article

References (63)

1. Baldwin Jr AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
2. O'Neill LA, Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997; 20: 252-258.
3. Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988; 242: 540-546.
4. May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998; 19: 80-88.
5. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-179.
6. Janssen-Heininger YM, Poynter ME, Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic Biol Med 2000; 28: 1317-1327.
7. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-6866.
8. Regnier CH et al. Identification and characterization of an IkappaB kinase. Cell 1997; 90: 373-383.
9. Woronicz JD et al. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 1997; 278: 866-869.
10. Burns K et al. MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem 1998; 273: 12203-12209.
11. Mochida Y et al. ASK1 inhibits interleukin-1-induced NF-kappa B activity through disruption of TRAF6-TAK1 interaction. J Biol Chem 2000; 275: 32747-32752.
12. Ng SB, Tan YH, Guy GR. Differential induction of the interleukin-6 gene by tumor necrosis factor and interleukin-1. J Biol Chem 1994; 269: 19021-19027.
13. Sparacio SM, Zhang Y, Vilcek J, Benveniste EN. Cytokine regulation of interleukin-6 gene expression in astrocytes involves activation of an NF-kappa B-like nuclear protein. J Neuroimmunol 1992; 39: 231-242.
14. Merola M, Blanchard B, Tovey MG. The kappa B enhancer of the human interleukin-6 promoter is necessary and sufficient to confer an IL-1 beta and TNF-alpha response in transfected human cell lines: requirement for members of the C/EBP family for activity. J Interferon Cytokine Res 1996; 16: 783-798.
15. Khaled AR, Butfiloski EJ, Sobel ES, Schiffenbauer J. Use of phosphorothioate-modified oligodeoxynucleotides to inhibit NF-kappaB expression and lymphocyte function. Clin Immunol Immunopathol 1998; 86: 170-179.
16. Kwon H et al. Inducible expression of IkappaBalpha repressor mutants interferes with NF-kappaB activity and HIV-1 replication in Jurkat T cells. J Biol Chem 1998; 273: 7431-7440.
17. Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995; 270: 24995-25000.
18. Singh S, Aggarwal BB. Protein-tyrosine phosphatase inhibitors block tumor necrosis factor-dependent activation of the nuclear transcription factor NF-kappa B. J Biol Chem 1995; 270: 10631-10639.
19. Tomita N et al. Transcription factor decoy for nuclear factor-kappaB inhibits tumor necrosis factor-alpha-induced expression of interleukin-6 and intracellular adhesion molecule-1 in endothelial cells. J Hypertens 1998; 16: 993-1000.
20. Tomita N et al. Transcription factor decoy for NFkappaB inhibits TNF-alpha-induced cytokine and adhesion molecule expression in vivo. Gene Therapy 2000; 7: 1326-1332.
21. Schmedtje JF et al. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997; 272: 601-608.
22. Ye SM, Johnson RW. Regulation of interleukin-6 gene expression in brain of aged mice by nuclear factor kappaB. J Neuroimmunol 2000; 117: 87-96.
23. Tomita T et al. Transcription factor decoy for NFkappaB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 749-757.
24. Morishita R et al. In vivo transfection of cis element 'decoy' against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997; 3: 894-899.
25. Ono S et al. Decoy administration of NF-kappaB into the subarachnoid space for cerebral angiopathy. Hum Gene Ther 1998; 9: 1003-1011.
26. Sharma HW et al. Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. Anticancer Res 1996; 16: 61-69.
27. Suzuki J et al. Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Therapy 2000; 7: 1847-1852.
28. Vos IH et al. NFkappaB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J 2000; 14: 815-822.
29. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994; 269: 10444-10450.
30. Pooga M, Hällbrink M, Zorko M, Langel Ü. Cell penetration by transportan. FASEB J 1998; 12: 67-77.
31. Pooga M et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol 1998; 16: 857-861.
32. Egholm M et al. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 1993; 365: 566-568.
33. Jensen KK, Orum H, Nielsen PE, Norden B. Kinetics for hybridization of peptide nucleic acids (PNA) with DNA and RNA studied with the BIAcore technique. Biochemistry 1997; 36: 5072-5077.
34. Troy CM et al. Downregulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway. J Neurosci 1996; 16: 253-261.
35. Griffin TJ, Smith LM. An approach to predicting the stabilities of peptide nucleic acid:DNA duplexes. Anal Biochem 1998; 260: 56-63.
36. Matsusaka T et al. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci USA 1993; 90: 10193-10197.
37. Akira S et al. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J 1990; 9: 1897-1906.
38. Vanden Berghe W et al. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 1998; 273: 3285-3290.
39. Vanden Berghe W et al. The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J Biol Chem 1999; 274: 32091-32098.
40. Hungness ES et al. The transcription factor activator protein-1 is activated and interleukin-6 production is increased in interleukin-1beta-stimulated human enterocytes. Shock 2000; 14: 386-391.
41. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 1990; 10: 2327-2334.
42. Sandler S et al. Decreased cell replication and polyamine content in insulin-producing cells after exposure to human interleukin 1 beta. Immunol Lett 1989; 22: 267-272.
43. Corbett JA et al. Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide. J Clin Invest 1992; 90: 2384-2391.
44. Eikelenboom P, Zhan SS, van Gool WA, Allsop D. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci 1994; 15: 447-450.
45. Bauer J et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett 1991; 285: 111-114.
46. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 2001; 22: 799-809.
47. Rogers J et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1992; 89: 10016-10020.
48. Boissiere F et al. Nuclear translocation of NF-kappaB in cholinergic neurons of patients with Alzheimer's disease. Neuroreport 1997; 8: 2849-2852.
49. Kitamura Y et al. Alteration of transcription factors NF-kappaB and STAT1 in Alzheimer's disease brains. Neurosci Lett 1997; 237: 17-20.
50. Terai K, Matsuo A, McGeer PL. Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res 1996; 735: 159-168.
51. Strauss S et al. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Lab Invest 1992; 66: 223-230.
52. Wood JA et al. Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res 1993; 629: 245-252.
53. Hull M et al. Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options. Neurobiol Aging 1996; 17: 795-800.
54. 2+ accumulation. Proc Natl Acad Sci USA 1995; 92: 9328-9332.
55. Taglialatela G, Robinson R, Perez-Polo JR. Inhibition of nuclear factor kappa B (NFkappaB) activity induces nerve growth factor-resistant apoptosis in PC12 cells. J Neurosci Res 1997; 47: 155-162.
56. Guo Q, Robinson N, Mattson MP. Secreted beta-amyloid precursor protein counteracts the proapoptotic action of mutant presenilin-1 by activation of NF-kappaB and stabilization of calcium homeostasis. J Biol Chem 1998; 273: 12341-12351.
57. Moerman AM, Mao X, Lucas MM, Barger SW. Characterization of a neuronal kappaB-binding factor distinct from NF-kappaB. Brain Res Mol Brain Res 1999; 67: 303-315.
58. Kunsch C, Ruben SM, Rosen CA. Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation. Mol Cell Biol 1992; 12: 4412-4421.
59. Schmid RM, Liptay S, Betts JC, Nabel GJ. Structural and functional analysis of NF-kappa B. Determinants of DNA binding specificity and protein interaction. J Biol Chem 1994; 269: 32162-32167.
60. Toledano MB, Ghosh D, Trinh F, Leonard WJ. N-terminal DNA-binding domains contribute to differential DNA-binding specificities of NF-kappa B p50 and p65. Mol Cell Biol 1993; 13: 852-860.
61. Langel Ü, Land T, Bartfai T. Design of chimeric peptide ligands to galanin receptors and substance P receptors. Int J Pept Protein Res 1992; 39: 516-522.
62. Egholm M, Buchart O, Nielsen PE, Berg RH. Peptide nucleic acids (PNA). Oligonucleotide analogues with an achiral peptide backbone. J Am Chem Soc 1992; 114: 1895-1897.
63. Gatti S, Bartfai T. Induction of tumor necrosis factor-alpha mRNA in the brain after peripheral endotoxin treatment: comparison with interleukin-1 family and interleukin-6. Brain Res 1993; 624: 291-294.